Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma-Reference-Cited by-同舟云学术

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

Published:2011-03-25 Issue:8 Volume:129 Page:1963-1969
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Mahmood S. Tariq,Agresta Samuel,Vigil Carlos E.,Zhao Xiuhua,Han Gang,D'Amato Gina,Calitri Ciara E.,Dean Michelle,Garrett Christopher,Schell Michael J.,Antonia Scott,Chiappori Alberto

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Combination chemotherapy for soft-tissue sarcomas: a phase III study;Cruz;J Surg Oncol,1979

2. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas;Edmonson;J Clin Oncol,1993

3. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group;Santoro;J Clin Oncol,1995

4. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma;Verma;Cancer Treat Rev,2008

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

2. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection;Cancers;2024-01-08

3. Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study;Frontiers in Pharmacology;2023-11-10

4. Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives;Diagnostics;2023-09-22

5. Renal Leiomyosarcoma: Unraveling the Mysteries of a Rare Malignancy;Cureus;2023-09-18